{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T07:03:32Z","timestamp":1780297412379,"version":"3.54.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplant Immunology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.trim.2026.102381","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T07:49:14Z","timestamp":1773906554000},"page":"102381","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["T315I-mutated chronic myeloid leukemia with blast crisis relapse 10\u00a0years after allo-HSCT: A case report of second transplantation combined with olverembatinib maintenance therapy"],"prefix":"10.1016","volume":"96","author":[{"given":"YuTing","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JiaJuan","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PeiWen","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YanQiu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ShengJin","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trim.2026.102381_bb0005","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/ajh.26642","article-title":"Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring","volume":"97","author":"Jabbour","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.trim.2026.102381_bb0010","unstructured":"R. Hehlmann, A. Hochhaus, Chronic myeloid leukaemia, (n.d.)."},{"key":"10.1016\/j.trim.2026.102381_bb0015","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1365-2141.2007.06582.x","volume":"137","author":"Giralt","year":"2007","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.trim.2026.102381_bb0020","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1200\/JCO.2009.26.7757","article-title":"Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase","volume":"28","author":"Goldman","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trim.2026.102381_bb0025","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1056\/NEJM199907013410103","article-title":"Long-term survival and late deaths after allogeneic bone marrow transplantation","volume":"341","author":"Soci\u00e9","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trim.2026.102381_bb0030","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13045-022-01334-z","article-title":"Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1\/2 trial","volume":"15","author":"Jiang","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.trim.2026.102381_bb0035","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s40265-022-01680-9","article-title":"Olverembatinib: first approval","volume":"82","author":"Dhillon","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.trim.2026.102381_bb0040","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13045-021-01159-2","article-title":"The consensus from the Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update","volume":"14","author":"Zhang","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.trim.2026.102381_bb0045","series-title":"European Leukemianet Recommendations for the Management of Chronic Myeloid Leukemia","author":"Baccarani","year":"2013"},{"key":"10.1016\/j.trim.2026.102381_bb0050","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/ajh.23282","article-title":"Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management","volume":"87","author":"Jabbour","year":"2012","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.trim.2026.102381_bb0055","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.leukres.2013.09.011","article-title":"Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia","volume":"38","author":"Soverini","year":"2014","journal-title":"Leuk. Res."},{"key":"10.1016\/j.trim.2026.102381_bb0060","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nrclinonc.2015.193","article-title":"Allogeneic transplantation for CML in the TKI era: striking the right balance","volume":"13","author":"Innes","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.trim.2026.102381_bb0065","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trim.2026.102381_bb0070","unstructured":"T. O'Hare, C.A. Eide, M.W.N. Deininger, Bcr-Abl Kinase Domain Mutations, Drug Resistance, and the Road to a Cure for Chronic Myeloid Leukemia, (n.d.)."},{"key":"10.1016\/j.trim.2026.102381_bb0075","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1038\/sj.leu.2403821","article-title":"A 10-year median follow-up study after allogeneic stem cell transplantation for chronic myeloid leukemia in chronic phase from HLA-identical sibling donors","volume":"19","author":"Robin","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.trim.2026.102381_bb0080","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/sj.bmt.1701729","article-title":"Relapse of chronic myeloid leukaemia 14 years after allogeneic bone marrow transplantation","volume":"23","author":"Yong","year":"1999","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.trim.2026.102381_bb0085","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0145-2126(01)00095-9","article-title":"Rapid clonal development in a relapsed CML 11 years post replete allogeneic bone marrow transplantation","volume":"26","author":"Kearney","year":"2002","journal-title":"Leuk. Res."},{"key":"10.1016\/j.trim.2026.102381_bb0090","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.leukres.2009.03.010","article-title":"Very late relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation","volume":"33","author":"Sekhri","year":"2009","journal-title":"Leuk. Res."},{"key":"10.1016\/j.trim.2026.102381_bb0095","first-page":"1","article-title":"Chronic myeloid Leukemia relapsing 25 years after allogenic stem cell transplantation","volume":"2018","author":"Reikvam","year":"2018","journal-title":"Case Rep. Hematol."},{"key":"10.1016\/j.trim.2026.102381_bb0100","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1007\/s00277-024-05649-4","article-title":"Late relapse of chronic myeloid leukemia after allogeneic bone marrow transplantation points to KANSARL (KANSL1::ARL17A) alteration: a case report with insights on the molecular landscape","volume":"103","author":"Fontana","year":"2024","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.trim.2026.102381_bb0105","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s12185-008-0092-5","article-title":"Relapse of chronic myeloid leukemia-chronic phase 14 years after allogeneic hematopoietic stem cell transplantation","volume":"88","author":"Akahane","year":"2008","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.trim.2026.102381_bb0110","unstructured":"C. Guglielmi, W. Arcese, J. Hermans, A. Bacigalupo, G. Bandini, D. Bunjes, E. Carreras, F. Frassoni, J. Goldman, A. Gratwohl, H.-J. Kolb, A.P. Iori, D. Niederwieser, H.G. Prentice, T. de Witte, Risk Assessment in Patients with Ph1 Chronic Myelogenous Leukemia at First Relapse after Allogeneic Stem Cell Transplant: An EBMT Retrospective Analysis, (n.d.)."},{"key":"10.1016\/j.trim.2026.102381_bb0115","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1038\/sj.leu.2403068","article-title":"For the chronic leukaemia working Party of the European Group of bone and marrow transplantation (EBMT), response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia","volume":"17","author":"Olavarria","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.trim.2026.102381_bb0120","unstructured":"J. Cortes, Ponatinib Dose-Ranging Study in Chronic-Phase Chronic Myeloid Leukemia: A Randomized, Open-Label Phase 2 Clinical Trial, (n.d.)."},{"key":"10.1016\/j.trim.2026.102381_bb0125","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome\u2013positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trim.2026.102381_bb0130","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1021\/jm301581y","article-title":"Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region\u2013Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib","volume":"56","author":"Ren","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.trim.2026.102381_bb0135","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s11899-021-00658-w","article-title":"Future directions in chronic phase CML treatment","volume":"16","author":"Javidi-Sharifi","year":"2021","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.trim.2026.102381_bb0140","unstructured":"K. Offit, J.P. Burns, I. Cunningham, S.C. Jhanwar, P. Black, N.A. Kernan, R.J. O'Reilly, R.S.K. Chaganti, Cytogenetic Analysis of Chimerism and Leukemia Relapse in Chronic Myelogenous Leukemia Patients After T Cell-Depleted Bone Marrow Transplantation, (n.d.)."},{"key":"10.1016\/j.trim.2026.102381_bb0145","unstructured":"D.J. DeAngelo, E.P. Hochberg, E.P. Alyea, J. Longtine, S. Lee, I. Galinsky, B. Parekkedon, J. Ritz, J.H. Antin, R.M. Stone, R.J. Soiffer, Extended Follow-up of Patients Treated with Imatinib Mesylate (Gleevec) for Chronic Myelogenous Leukemia Relapse after Allogeneic Transplantation: Durable Cytogenetic Remission and Conversion to Complete Donor Chimerism without Graft-versus-Host Disease, (n.d.)."},{"key":"10.1016\/j.trim.2026.102381_bb0150","doi-asserted-by":"crossref","unstructured":"A. Tefferi, T. Barbui, Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management, Am. J. Hematol. 90 (2015) 162\u2013173. Doi: https:\/\/doi.org\/10.1002\/ajh.23895.","DOI":"10.1002\/ajh.23895"},{"key":"10.1016\/j.trim.2026.102381_bb0155","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2024.1391078","article-title":"Chronic myeloproliferative neoplasms with concomitant CALR mutation and BCR::ABL1 translocation: diagnostic and therapeutic implications of a rare hybrid disease","volume":"12","author":"Zanelli","year":"2024","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.trim.2026.102381_bb0160","doi-asserted-by":"crossref","DOI":"10.1111\/ijlh.12792","article-title":"Chronic myeloid leukemia, BCR - ABL 1-positive with CALR and MPL mutations","volume":"40","author":"Klairmont","year":"2018","journal-title":"Int. J. Lab. Hematol."},{"key":"10.1016\/j.trim.2026.102381_bb0165","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1182\/blood-2014-12-616847","article-title":"CALR-mutated essential thrombocythemia evolving to chronic myeloid leukemia with coexistent CALR mutation and BCR-ABL translocation","volume":"125","author":"Bonzheim","year":"2015","journal-title":"Blood"}],"container-title":["Transplant Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327426000390?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327426000390?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T06:48:24Z","timestamp":1780296504000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0966327426000390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":33,"alternative-id":["S0966327426000390"],"URL":"https:\/\/doi.org\/10.1016\/j.trim.2026.102381","relation":{},"ISSN":["0966-3274"],"issn-type":[{"value":"0966-3274","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"T315I-mutated chronic myeloid leukemia with blast crisis relapse 10\u00a0years after allo-HSCT: A case report of second transplantation combined with olverembatinib maintenance therapy","name":"articletitle","label":"Article Title"},{"value":"Transplant Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trim.2026.102381","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102381"}}